Insight into the Oseltamivir Resistance R292K Mutation in H5N1 Influenza Virus: A Molecular Docking and Molecular Dynamics Approach

Cell Biochemistry and Biophysics

Volumn 68, Issue 2, 2014, Pages 291-299

  Karthick, V ^a   Ramanathan, K ^a  

^a VIT UNIVERSITY   (India)

Author keywords

Molecular docking; Molecular dynamic simulation; Neuraminidase; Oseltamivir resistance; Potential of mean force

Indexed keywords

ANTIVIRUS AGENT; OSELTAMIVIR; SIALIDASE;

ANTIVIRAL RESISTANCE; ARTICLE; BINDING SITE; CHEMISTRY; GENETICS; INFLUENZA VIRUS A H5N1; METABOLISM; MOLECULAR DOCKING; MUTATION; PROTEIN TERTIARY STRUCTURE; THERMODYNAMICS;

ANTIVIRAL AGENTS; BINDING SITES; DRUG RESISTANCE, VIRAL; INFLUENZA A VIRUS, H5N1 SUBTYPE; MOLECULAR DOCKING SIMULATION; MUTATION; NEURAMINIDASE; OSELTAMIVIR; PROTEIN STRUCTURE, TERTIARY; THERMODYNAMICS;

EID: 84893968205     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-013-9709-2     Document Type: Article

References (48)

1. Malik Peiris, J. S., de Jong, M. D., & Guan, Y. (2009). Avian influenza virus (H5N1) a treat to Human Health. Clinical Microbiology Reviews, 2, 243-267.
2. Peiris, J. S., Yu, W. C., Leung, C. W., Cheung, C. Y., Ng, W. F., Nicholls, J. M., et al. (2004). Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet, 363, 617-619.
3. Mase, M., Tsukamoto, K., Imada, T., Imai, K., Tanimura, N., Nakamura, K., et al. (2005). Characterization of H5N1 influenza A viruses isolated during the 2003-2004 influenza outbreaks in Japan. Virology, 332, 167-176.
4. WHO. (2010). Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO.
5. Zhou, H., Yu, Z., Hu, Y., Tu, J., Zou, W., et al. (2009). The special neuraminidase stalk-motif responsible for increased virulence and pathogenesis of H5N1 influenza A virus. PLoS ONE, 4, e6277.
6. Wiley, D. C., Skehel, J. J., & Waterfield, M. (1977). Evidence from studies with a cross-linking reagent that the haemagglutinin of influenza virus is a trimer. Virology, 79, 446-448.
7. Wilson, I. A., Skehel, J. J., & Wiley, D. C. (1981). Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution. Nature, 289, 366-373.
8. Su, B., Wurtzer, S., Rameix-Welti, M. A., Dwyer, D., van der Werf, S., Naffakh, N., et al. (2009). Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA). PLoS ONE, 4, e8495.
9. Peiris, J. S., Poon, L. L., & Guan, Y. (2009). Emergence of a novel swine-origin influenza A virus (S-OIV) H1N1 virus in humans. Journal of Clinical Virology, 4, 169-173.
10. von Itzstein, M., Wu, W. Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., et al. (1993). Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature, 363, 418-423.
11. Kim, C. U., Lew, W., Williams, M. A., Liu, H., Zhang, L., Swaminathan, S., et al. (1997). Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. Journal of the American Chemical Society, 119, 681-690.
12. Gubareva, L. V., Kaiser, L., & Hayden, F. G. (2000). Influenza virus neuraminidase inhibitors. Lancet, 355, 827-835.
13. Bucher, D. J., & Kilbourne, E. D. (1972). A 2 (N2) neuraminidase of the X-7 influenza virus recombinant: Determination of molecular size and subunit composition of the active unit. Journal of Virology, 10, 60-66.
14. Le, Q. M., Kiso, M., Someya, K., Sakai, Y. T., Nguyen, T. H., Nguyen, K. H., et al. (2005). Avian flu: Isolation of drug-resistant H5N1 virus. Nature, 437, 1108.
15. de Jong, M. D., Tran, T. T., Truong, H. K., Vo, M. H., Smith, G. J., Nguyen, V. C., et al. (2005). Oseltamivir resistance during treatment of influenza A (H5N1) infection. The New England Journal of Medicine, 353, 2667-2672.
16. Kiso, M., Mitamura, K., Sakai-Tagawa, Y., Shiraishi, K., Kawakami, C., Kimura, K., et al. (2004). Resistant influenza A viruses in children treated with oseltamivir: Descriptive study. Lancet, 364, 759-765.
17. Inoue, M., Barkham, T., Leo, Y. S., Chan, K. P., Chow, A., Wong, C. W., et al. (2010). Emergence of oseltamivir-resistant pandemic (H1N1) 2009 virus within 48 hours. Emerging Infectious Diseases, 6, 1633-1636.
18. Hatakeyama, S., Sugaya, N., Ito, M., Yamazaki, M., Ichikawa, M., Kimura, K., et al. (2007). Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA, 297, 1435-1442.
19. Ciancio, B. C., Meerhoff, T. J., Kramarz, P., Bonmarin, I., Borgen, K., et al. (2009). Oseltamivir-resistant influenza A (H1N1) viruses detected in Europe during season 2007-8 had epidemiologic and clinical characteristics similar to co-circulating susceptible A(H1N1) viruses. Eurosurveillance, 14, 19412.
20. Durrant, J. D., & McCammon, J. A. (2011). Molecular dynamics simulations and drug discovery. BMC Biology, 9, 71-79.
21. Karthick, V., Shanthi, V., Rajasekaran, R., & Ramanathan, K. (2012). Exploring the cause of oseltamivir resistance against mutant H274Y neuraminidase by molecular simulation approach. Applied Biochemistry and Biotechnology, 167, 237-249.
22. Karthick, V., Shanthi, V., Rajasekaran, R., & Ramanathan, K. (2012). In silico analysis of drug-resistant mutant of neuraminidase (N294S) against oseltamivir. Protoplasma, 250, 197-207.
23. Chachra, R., & Rizzo, R. C. (2008). Origins of resistance conferred by the R292K neuraminidase mutation via molecular dynamics and free energy calculations. Journal of Chemical Theory and Computation, 4, 1526-1540.
24. Cheng, L. S., Amaro, R. E., Xu, D., Li, W. W., Arzberger, P. W., & McCammon, J. A. (2008). Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase. Journal of Medicinal Chemistry, 51, 3878-3894.
25. Gamblin, S. J., & Skehel, J. J. (2010). Influenza hemagglutinin and neuraminidase membrane glycoproteins. The Journal of Biological Chemistry, 285, 28403-28409.
26. Russell, R. J., Haire, L. F., Stevens, D. J., Collins, P. J., Lin, Y. P., Blackburn, G. M., et al. (2006). The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature, 443, 45-49.
27. Von Itzstein, M. (2007). The war against influenza: Discovery and development of sialidase inhibitors. Nature Reviews Drug Discovery, 6, 967-974.
28. Baştug, T., Chen, P. C., Patra, S. M., & Kuyucak, S. (2008). Potential of mean force calculations of ligand binding to ion channels from Jarzynski's equality and umbrella sampling. Journal of Chemical Physics, 128, 155104.
29. Hub, J. S., de Groot, B. L., & van der Spoel, D. (2010). g_wham-A free weighted histogram analysis implementation including robust error and autocorrelation estimates. Journal of Chemical Theory and Computation, 6, 3713-3720.
30. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., et al. (2000). The protein data bank. Nucleic Acids Research, 28, 235-242.
31. Guex, N., & Peitsch, M. C. (1997). SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis, 18, 2714-2723.
32. Feldman, J., Snyder, K. A., Ticoll, A., Pintilie, G., & Hogue, C. W. (2006). A complete small molecule dataset from the protein data bank. FEBS Letters, 580, 1649-1653.
33. Gasteiger, J., Rudolph, C., & Sadowski, J. (1990). Automatic generation of 3D-atomic coordinates for organic molecules. Tetrahedron Computer Methodology, 3, 537-547.
34. Lopez, G., Valencia, A., & Tress, M. L. (2007). Firestar-Prediction of functionally important residues using structural templates and alignment reliability. Nucleic Acids Research, 35, 573-577.
35. Colman, P. M., Varghese, J. N., & Laver, W. G. (1983). Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature, 303, 41-44.
36. Thompson, M. A. (2004). Poster presentation: molecular docking using ArgusLab: An efficient shape-based search algorithm and the AScore scoring function. In Fall ACS Meeting, Philadelphia, PA.
37. Wallace, A. C., Laskowski, R. A., & Thornton, J. M. (1995). LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. Protein Engineering, Design and Selection, 8, 127-134.
38. Warren, L. D. (2002). The PyMOL molecular graphics system. San Carlos, CA: DeLano Scientific LLC.
39. Hess, B., Kutzner, C., Spoel, D., & Lindahl, E. (2008). GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. Journal of Chemical Theory and Computation, 4, 435-447.
40. Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., & Berendsen, H. J. (2005). GROMACS: Fast, flexible, and free. Journal of Computational Chemistry, 26, 1701-1718.
41. Meagher, K. L., & Carlson, H. A. (2005). Solvation influences flap collapse in HIV-1 protease. Proteins: Structure Function, and Bioinformatics, 58, 119-125.
42. Schuttelkopf, A. W., & van Aalten, D. M. F. (2004). PRODRG-a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallographica, 60, 1355-1363.
43. Darden, T., Perera, L., Li, L., & Pedersen, L. (1999). New tricks for modelers from the crystallography toolkit: The particle mesh Ewald algorithm and its use in nucleic acid simulations. Structure, 7, 55-60.
44. Lindahl, E., Hess, B., & van der Spoel, D. (2001). GROMACS 3. 0: A package for molecular simulation and trajectory analysis. Journal of Molecular Modeling, 7, 306-317.
45. Han, L. Y., Lin, H. H., Li, Z. R., Zheng, C. J., Cao, Z. W., Xie, B., et al. (2006). PEARLS: Program for energetic analysis of receptor-ligand system. Journal of Chemical Information and Modeling, 46, 445-450.
46. Schneidman, D., Inbar, Y., Nussinov, R., & Wolfson, H. J. (2006). PatchDock and SymmDock: Servers for rigid and symmetric docking. Nucleic Acids Research, 33, 363-367.
47. Han, N., Liu, X., & Mu, Y. (2012). Exploring the mechanism of zanamivir resistance in a neuraminidase mutant: A molecular dynamics study. PLoS ONE, 7, e44057.
48. Varghese, J. N., Smith, P. W., Sollis, S. L., Blick, T. J., Sahasrabudhe, A., McKimm-Breschkin, J. L., et al. (1998). Drug design against a shifting target: A structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure, 6, 735-746.